MENU
+Compare
INO
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$2.24
Change
+$0.02 (+0.90%)
Capitalization
80.68M

INO Inovio Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of synthetic vaccines and immune therapies for cancers and infectious diseases

Industry Biotechnology
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for INO with price predictions
Feb 18, 2025

Momentum Indicator for INO turns positive, indicating new upward trend

INO saw its Momentum Indicator move above the 0 level on February 12, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned positive. In of the 78 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.097) is normal, around the industry mean (12.604). P/E Ratio (0.000) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). INO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (277.778) is also within normal values, averaging (252.111).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. INO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

INO is expected to report earnings to rise 1,266.67% to -123 cents per share on March 13

Inovio Pharmaceuticals INO Stock Earnings Reports
Q4'23
Est.
$-1.23
Q3'23
Beat
by $0.04
Q2'23
Beat
by $0.02
Q1'23
Beat
by $0.31
Q4'22
Missed
by $0.05
The last earnings report on November 09 showed earnings per share of -9 cents, beating the estimate of -12 cents. With 1.40M shares outstanding, the current market capitalization sits at 80.68M.
A.I. Advisor
published General Information

General Information

a developer of synthetic vaccines and immune therapies for cancers and infectious diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
660 West Germantown Pike
Phone
+1 267 440-4200
Employees
122
Web
https://www.inovio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

INO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with RPTX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
+1.86%
RPTX - INO
50%
Loosely correlated
+0.79%
EDIT - INO
48%
Loosely correlated
+26.09%
ONCO - INO
43%
Loosely correlated
-7.42%
DNLI - INO
39%
Loosely correlated
+1.97%
BCYC - INO
38%
Loosely correlated
-3.11%
More